Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
Jorge Berlanga‐Acosta(Centro de Ingeniería Genética y Biotecnología), Luis Herrera-Martínez(Centro de Ingeniería Genética y Biotecnología), Ernesto López‐Mola(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Jorge Gavilondo‐Cowley(Centro de Ingeniería Genética y Biotecnología), María D Castro‐Santana(Centro de Ingeniería Genética y Biotecnología), Tania González‐López(United States Nuclear Regulatory Commission), Pedro López‐Saura(United States Nuclear Regulatory Commission)
Cited by 167
Related Papers
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134
Domain III of the envelope protein as a dengue vaccine target
|Expert Review of Vaccines|2010|125